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ABSTRACT
THE ROLE OF CLOT STRUCTURE AND MECHANICS ON HEMODYNAMICS AND
PHARMACOLOGY
Michael DeCortin
Scott L. Diamond
Hemostatic clots have a core/shell hierarchy comprised of a P-selectin positive core
surrounded by a P-selectin negative shell. A new human blood microfluidic assay utilizing a 2stage assay was developed to interrogate core/shell mechanics. By first perfusing whole blood
over a collagen/TF surface and then swapping out the blood for buffer, we were able to pause
thrombus growth at a specific point in time. The shear rate was then drastically increased to
interrogate platelet-platelet interactions. We found that thrombin inhibition, but not fibrin, led to
greater erosion of the thrombus, and that the core region of the thrombus was stable with or
without the presence of fibrin. Next, we tested the effects of ADP or TxA2 inhibitors on thrombus
growth and stability. We found that inhibiting TxA2 production did not affect platelet deposition,
but the platelets that did attach to the clot were more likely to erode after being subjected to
shear. Both P2Y1 and P2Y12 antagonism led to decreased initial platelet deposition and more
platelet erosion. P2Y12 signaling had the most significant effect on deposition and stability
suggesting that it might have an amplification effect on other signaling pathways. We
demonstrated a new method to examine thrombus strength and stability and showed the effect
of thrombin on core size along with the importance of secondary agonists on stability in the shell
region.
We used an 8-channel microfluidic device to examine the efficacy of ex vivo apixaban
on platelet and fibrin deposition in neonates with CHD. This patient population was shown to
have significantly more activity blood after surgery. We found that apixaban drastically lowers
coagulation activity in neonatal blood before and after surgery and significantly prolongs
occlusion time to a greater extent than adults. We also demonstrated that andexanet alfa
reverses the inhibitory effect of apixaban in both neonates and adults. These results
iv

demonstrated that microfluidics is a useful way to examine pharmacological effects, especially in
a population where only small quantities of blood can be drawn.

v

TABLE OF CONTENTS

ACKNOWLEDGMENT .................................................................................................................. iii
ABSTRACT ................................................................................................................................... iv
LIST OF ILLUSTRATIONS .......................................................................................................... vii
CHAPTER 1 – INTRODUCTION ................................................................................................... 1
1.1 Thrombosis and Hemostasis ............................................................................................ 1
1.2 Platelets and the Coagulation Cascade ........................................................................... 2
1.3 Hemodynamics ................................................................................................................... 4
1.4 Microfluidics to study coagulation biology ..................................................................... 5
CHAPTER 2 – CORE AND SHELL PLATELETS: A NEW MICROFLUIDIC ASSAY TO STUDY
MECHANICS AND BIOCHEMISTRY ............................................................................................ 8
2.1 Design of a microfluidic device to interrogate the mechanics and biochemistry of
the core and shell platelets of a human thrombus ............................................................... 8
2.1.1 Introduction .................................................................................................................... 8
2.1.2 Materials and Methods .................................................................................................. 9
2.1.3 Results ......................................................................................................................... 12
2.1.4 Discussion ................................................................................................................... 23
CHAPTER 3 – WHOLE BLOOD MICROFLUIDICS TO ASSESS DIRECT ORAL
ANTICOAGULANTS (DOACs) ACTIVITY AND REVERSAL IN NEONATAL CARDIAC
PATIENTS .................................................................................................................................... 25
3.1 Ex vivo apixaban lowers thrombotic activity in neonatal cardiac patients to a higher
degree than adults .................................................................................................................. 25
3.1.1 Introduction .................................................................................................................. 25
3.1.2 Materials and Methods ................................................................................................ 26
3.1.3 Results ......................................................................................................................... 28
3.1.4 Discussion ................................................................................................................... 34
3.2 Andexanet alfa restores coagulation activity lowered by apixaban in both adults and
neonates .................................................................................................................................. 35
3.2.1 Materials and Methods ................................................................................................ 35
3.2.2 Results ......................................................................................................................... 36
3.2.3 Discussion ................................................................................................................... 39
CHAPTER 4 – FUTURE WORK .................................................................................................. 41
4.1 Core platelets of a thrombus resist contractile forces ................................................. 41
4.2 Incorporation of fluorescence beads into thrombi ....................................................... 45
APPENDIX ................................................................................................................................... 48
BIBLIOGRAPHY .......................................................................................................................... 50

vi

LIST OF ILLUSTRATIONS

Figure 1-1: Primary and secondary hemostasis ............................................................................. 1
Figure 1-2: Platelet activation ......................................................................................................... 2
Figure 1-3: Coagulation Cascade................................................................................................... 4
Figure 1-4: Photolithography .......................................................................................................... 6
Figure 1-5: 8-channel microfluidic device ....................................................................................... 7
Figure 2-1: Procedure to investigate clot stability and morphology ............................................. 11
Figure 2-2: A taller microfluidic device increases occlusion time which widens the window to
probe clot morphology and stability. ............................................................................................. 12
Figure 2-3: Perfusion of buffer over thrombi allows for the probing of stability and morphology in
a shear dependent manner .......................................................................................................... 14
Figure 2-4: Tissue factor significantly increases clot stability and number of highly activated
platelets at both low and high shear rates when absorbed to the collagen surface .................... 15
Figure 2-5: Thrombin inhibition, but not fibrin inhibition, decreases overall thrombus stability
while the core remains stable under all conditions ....................................................................... 17
Figure 2-6: Inhibiting thrombin production decreases the number of platelets left at the end of the
experiment by limiting core size ................................................................................................... 18
Figure 2-7: Aspirin lowered initial platelet deposition and decreased the stability of shell platelets
when subjected to shear .............................................................................................................. 19
Figure 2-8: A P2Y1 inhibitor lowered initial platelet deposition and decreased stability of shell
platelets when subjected to shear ................................................................................................ 20
Figure 2-9: A P2Y12 inhibitor lowered initial platelet deposition and decreased stability of shell
platelets when subjected to shear ................................................................................................ 21
Figure 2-10: Confocal images show clear core/shell morphology ............................................... 22
Figure 3-1: Thrombotic activity of healthy adults and at-risk neonates ........................................ 29
Figure 3-2: Patient population before and after surgery............................................................... 30
Figure 3-3: Prostaglandin treatment prior to surgery ................................................................... 31
Figure 3-4: The effect of apixaban on platelet and fibrin deposition ............................................ 32
Figure 3-5: The effect of apixaban on thrombotic activity and occlusion time ............................. 33
Figure 3-6: The effect of andexanet alfa on healthy adults .......................................................... 36
Figure 3-7: Andexanet alfa is capable of reversing the effects of apixaban ................................ 37
Figure 3-8: Andexanet alfa has no effect on thrombotic activity at 50 µg/mL .............................. 38
Figure 3-9: Andexanet alfa restores platelet and fibrin activity in neonates after surgery ........... 39
Figure 4-1: PPACK lowers P-selectin expression and 2-MeSAMP lowers both total platelet
accumulation and P-selectin expression ...................................................................................... 43
Figure 4-2: Core platelets of the thrombus resist contraction ...................................................... 44
Figure 4-3: Fluorescence beads are an indicator of contraction when there is no fibrin present 46
Figure 4-4: Demonstration of particle tracking via ImageJ ........................................................... 47
Supplemental Figure I: The 120 µm height channel has a slightly less uniform shear rate than
the 60 µm height but does not significantly affect dynamics. ....................................................... 48
Supplemental Figure II: Procedure to fix clots to image with confocal before and after shear .... 48
Supplemental Figure III: A 60 µm tall channel can be used to look at clot stability under certain
conditions ..................................................................................................................................... 49
Supplemental Figure IV: Blood can be swapped out for buffer at later time points ..................... 49
Supplemental Figure V: Procedure to calculate percent contraction ........................................... 50

vii

CHAPTER 1 – INTRODUCTION
1.1 Thrombosis and Hemostasis
Hemostasis is defined as the cessation of blood flow following damage to a blood vessel
(1). Normally, the endothelium maintains an anticoagulant surface that keeps blood in a liquid
state, but upon injury, the subendothelial matrix is exposed which provides a procoagulant
surface for thrombus growth (2). There are two phases in hemostasis, primary and secondary
hemostasis. Primary hemostasis is driven by the initial aggregation of platelets which adhere to
collagen, von Willebrand Factor (vWF), and other proteins which results in the formation of a
platelet plug (3,4). The initially adhered platelets become activated and release secondary
agonists such as ADP and Thromboxane A2 (TxA2) (5,6). Secondary hemostasis occurs through
the production of thrombin via the intrinsic and extrinsic pathways of the coagulation cascade (7).
Thrombin serves a dual role by acting as both a platelet activator and as an enzyme to convert
fibrinogen to fibrin (8). A hemostatic plug is shown in Figure 1-1 (9).

Figure 1-1: Primary and secondary hemostasis
Primary hemostasis: platelets adhere to the exposed subendothelial matrix and produce agonists
which leads to the formation of a platelet plug. The platelet plug is surrounded by fibrin which is
formed via the coagulation cascade in secondary hemostasis.
Thrombosis is a pathological condition that occurs when a thrombus builds up within the
lumen of a diseased vessel (9). This build up leads to an obstructed blood flow and can
potentially result in full vessel blockage. Thrombosis is associated with a number of life1

threatening diseases such as stroke and coronary artery disease (10). While thrombosis is a
pathological condition and hemostasis is a normal response to vessel injury, the fundamental
coagulation biology between the two is the same (1), and the study of coagulation can be
applicable to both.
1.2 Platelets and the Coagulation Cascade
Platelets, or thrombocytes, are anucleate cells produced from megakaryocytes that
circulate within the blood and are the primary drivers of thrombus formation (11). Platelets are
inhibited by nitric oxide, thrombomodulin, and prostaglandin I2 under normal conditions (9,12,13).
As previously mentioned, platelets can become activated when the subendothelial matrix is
exposed. There are many different receptors that can initiate platelet activation as outlined in

Figure 1-2: Platelet activation
Platelets are inhibiting by numerous compounds produced from endothelial cells such as nitric
oxide. Platelet activation is initiated by exposure to proteins such as collagen or vWF. They are
further activated by ADP, TxA2, and thrombin which resulting in large increases in intracellular
calcium. This results in inside-out signaling, granule secretion, and PtdSer exposure.
2

Figure 1-2 (12). Namely, collagen binds to αIIβI and GPVI and vWF binds to the GP1b-V-IX
complex (14,15). Additionally, primary activation of platelets occurs via the binding of thrombin
onto two different Gαq-coupled receptors, PAR1 and PAR4 (16,17). Platelets can also be
activated via less potent agonists than thrombin, known as secondary agonists. These agonists
include ADP, which binds onto two different receptors, P2Y12 and P2Y1, and TxA2 which binds
onto the TP receptor(6,18–20) . Of note, Gi signaling (P2Y12) cannot stimulate platelet activation
on its own, but it amplifies the platelet response to activation of receptors coupled to Gq (TP,
P2Y1, PAR1/4) (18,21,22). However, thrombin is a strong enough agonist to highly activate
platelets without the need of Gi signaling. As the platelets become more activated, their
intracellular Ca2+ levels increase, resulting in a number of important actions. The most important
mechanism for thrombus growth is inside-out signaling which results in the expression of many
integrins including αIIaβ3 on the platelet surface (23,24). Fibrinogen can then bind on to this
integrin on two different platelets resulting in platelet-platelet interaction. This linkage allows for
the build-up of a platelet plug. Intracellular calcium also results in TxA2 release, alpha and dense
granule release (25), and in the maximally activated platelets, phosphatidylserine exposure (26).
All these actions result in further activation of the platelet and other surrounding platelets.
The coagulation cascade is a series of reactions that occurs alongside platelet activation
that results in thrombin and fibrin production. The reactions are shown in Figure 1-3. There are
two different pathways in the coagulation cascade, the intrinsic (contact) and the extrinsic (tissue
factor) pathway. The intrinsic pathway starts with the activation of FXII with HMW kininogen and
prekallekerin (27). This is followed by the activation of factors XI and IX. The extrinsic pathway
begins with the conversion of FVII to FVIIa via tissue factor (28). These two pathways led to the
common pathway where factors X and V are first activated and then thrombin is produced via
conversion of prothrombin. For this to occur, a complex is formed with factors Xa, Va, and platelet
phospholipids (29). The thrombin that is produced cleaves fibrinogen resulting in fibrin formation
and also converts factor XIII to an active form to allow for the crosslinking of fibrin meshes (30).
3

Thrombin also amplifies the coagulation cascade by further activating factors V, VIII, and XI (31).
These two processes, coagulation and platelet activation, result in a fully formed thrombus.

Figure 1-3: Coagulation Cascade
The generation of thrombin and fibrin results from a series of reactions. The cascade can be
initiated through either the contact pathway or the tissue factor pathway. These lead to the
formation of a Xa-Va complex that converts prothrombin to thrombin. Thrombin then cleaves
fibrinogen to produce fibrin.
1.3 Hemodynamics
Within a blood vessel, platelet concentrations are several times higher at the vessel wall
than the center of the vessel. This phenomenon is known as platelet margination and helps
platelets adhere to exposed surfaces (32,33). Once they adhere, they need to be able to
withstand the shear forces exerted on them from the flowing blood. Throughout the human body,
there are many different flow rates and therefore shear rates that platelets can be subjected to
ranging from 50-60 s-1 in vena cava up to 5000 s-1 in arterioles (34,35). Under venous shear
conditions, platelets are able to resist shear just through binding to collagen via αIIβI and GPVI.
4

However, at high shear rates, vWF becomes vital for the stability of platelets (36,37). As the
thrombus grows, large numbers of αIIaβ3 are expressed on the platelet surface which fibrinogen
binds onto. The fibrinogen can link onto other nearby platelets providing further stability for the
platelet mass. To accurately study coagulation ex vivo, a microfluidic approach is required to
replicate the hemodynamics found within the body.
1.4 Microfluidics to study coagulation biology
Animal models are a popularly used method to study thrombosis and hemostasis, yet
these models are limited by inter-species differences, physiological variations between individual
animals, and lengthy ethical approval processes.(38,39) There has been extensive research in
blood coagulation under stagnant conditions (34,40–43), but these studies cannot replicate the
complex hemodynamic and platelet mechanobiology conditions found in vivo. In vitro
microfluidics allows for precise control of important clotting factors while closely replicated the in
vivo environment (34). For these reasons, there is a need to study coagulation biology through
the lenses of microfluidics under relevant hemodynamic conditions.
Originally, parallel platelet flow chambers were used that required 1 to 10 mL of blood
(44). This large volume of blood limited the amount of testing that can be down from a single draw
or collection of blood. Plate viscometers and thromboelastomers have also been commonly used
to study human blood samples, but they do not accuracy replicate vascular architecture (41,45).
To avoid these issues, open microfluidic systems are able to create physiological relevant venous
(100 – 200 s-1) or arterial shear rates (1000 – 2000 s-1) with very small quantities of blood (< 100
μL) through the use of dimensions that are on the same scale as in vivo systems.

5

There have been many advances in the technology utilized for microfluidics over the
years. The wide variety of devices created have sought to model bleeding to study various
phenomena such as thrombus permeability, thrombus contraction, stenosis, microcapillary flow,
angiogenesis, and endothelial activation (46–50). The advent of poly(dimethylsiloxane) (PDMS)
and photolithography has allowed for the creation of flow channels with features as small as 5
microns (51,52). The methods to create silicon molds for PDMS has been well studied; briefly, a
photoresistive substance is spin coated on a silicon wafer to an appropriate channel height. A
high-resolution mask of the desired dimensions is created via computer aided design and then
placed on top of the photoresist. The substrate is then exposed to UV light and the mask shields
certain parts of the photoresistive compound. After removing the mask and photoresistive layer,
the resulting master mold can be used hundreds of times to create PDMS devices. This method
is outlined in Figure 1-4 (51).

Figure 1-4: Photolithography
To create a silicon master mold to produce PDMS devices on, a photoresist is first spun onto the
wafer surface. A mask is then placed over the photoresist and is exposed to UV light. The
photoresist can then be removed resulting in a silicon mold that be used to create exact replicates
of the same device each time.
6

Recently, an 8-channel microfluidic device with multiple inlets and a single outlet has
been used to study a large range of coagulation conditions and problems. It has been used to
study mouse blood, healthy adult blood, and the blood of an at-risk neonate population. Studies
have looked at the effects of P2Y12/P2Y1 inhibitors, thrombin/fibrin inhibitors, thromboxane A2
inhibitors at venous, arterial, and pathological conditions (53–63). Data generated from this
device is reproducible and reliable and is generated from a small volume of blood. The 8-channel
device has been shown to be a robust assay to examine coagulation biology under many different
conditions.

Figure 1-5: 8-channel microfluidic device
An 8-channel microfluidic device is capable of observing the effect of different antagonists on
adult human whole blood.
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CHAPTER 2 – CORE AND SHELL PLATELETS: A NEW MICROFLUIDIC ASSAY TO STUDY
MECHANICS AND BIOCHEMISTRY
2.1 Design of a microfluidic device to interrogate the mechanics and biochemistry of the
core and shell platelets of a human thrombus

2.1.1 Introduction
Under physiological conditions, platelets are kept quiescent by endothelial cell production
of molecules such as nitric oxide and prostaglandin I2 (64). In the event of vascular injury or
inflammation, this inhibition is suppressed and results in platelet activation and accumulation (65).
Agonists of varying potencies such as adenosine 5’-diphosphate (ADP), thromboxane A2 (TxA2),
thrombin, and collagen activate platelets through receptor-mediated signaling (12). Alongside
platelet activation, tissue factor (TF) triggers fibrin generation via thrombin production (66)
resulting in a thrombus comprised of platelets linked via fibrinogen with a interspersed fibrin
mesh. As a thrombus is formed, platelets are activated non-uniformly (67) and heterogenous
intracellular calcium mobilization (68) results in differing populations of platelets with respect to Pselectin expression, granule release, and phosphatidylserine exposure. Highly activated platelets
undergo pseudopod formation and α-granule release, (12,25) whereas less activated platelets
retain their discoid morphology (46,67).
In vivo mouse models drive a core/shell hierarchy during the hemostatic response to
injury (18,69–71). This organization consists of a tightly packed, highly activated core of platelets
that are P-selectin positive and a loosely packed, less activated shell of P-selectin negative
platelets. Similar core/shell architecture comprised of a P-selectin positive core localized at the
collagen surface surrounded by a P-selectin negative shell is observed with human blood
perfused over prothrombotic surfaces (60). Transthrombus pressure gradients from the lumen to
the interstitial space that reduce local thrombin also reduce the thickness of the P-selectin
positive core region (60). The stability of a thrombus can influence whether it will grow to
8

occlusion or not. Importantly, as a clot grows into the flow field, the shear forces increase on the
clot surface as the lumen is reduced until the approach of the vessel occlusion when flow ceases.
Causes of (in)stability have been examined for a wide variety of proteins ranging from receptors
and membrane proteins (72–74) to plasma proteins (75–78) to intracellular signaling proteins
(79,80). Even though there is overlap in which pathways appear to be important in both thrombus
stability and growth, there appears to be differences between the two. Therefore, we have
developed a two-stage microfluidic assay to measure the mechanics of the core/shell clot
architecture using human blood.
In vitro microfluidic devices allows for precise control over flow fields, prothrombotic
surfaces, and imaging resolution (49). Previous research has shown the presence of core/shell
morphology in thrombi formed in both side-view (59) and stagnation point devices (81). A device
comprised of 8 identical parallel channels has been utilized to study thrombus growth through the
use of immunofluorescence (34,53,56,82). This 8-channel device allows for many conditions or
replicates to be studied for a single donor. The goal of this study is to use in vitro microfluidics to
study platelet activation, specifically core/shell morphology, in the context of thrombus stability
using a two-step process with a modified 8-channel device. The modification to the 8-channel is
an extended height (120 µm vs 60 µm) to prevent occlusion from occurring at early time points.

2.1.2 Materials and Methods
Whole blood (WB) was collected in 40 µg/mL corn trypsin inhibitor (CTI, Haematologic
Technologies, Essex Junction, VT, USA) or 100 µM D-Phe-Pro-Arg-CMK (PPACK, Haematologic
Technologies) from healthy donors who self-reported to be free of oral medication for at least 10
days prior to phlebotomy. All blood was collected under approval of the University of
Pennsylvania’s Institutional Review Board. Whole blood was treated with various reagents: 5 mM
H-Gly-Pro-Arg-Pro-OH acetate salt (GPRP, Bachem Americas, Torrance, CA, USA), 50 µM
acetylsalicylic acid (ASA, Sigma, St. Louis, Mo, USA), 100 µM MRS-2179 (Tocris, Minneapolis,
MN, USA), or 100 µM 2-Methylthioadenosine 5′-monophosphate triethylammonium salt hydrate
9

(2-MeSAMP, Sigma, St. Louis, Mo, USA). Platelets were labeled with an AF488 mouse antihuman CD61 antibody (Biorad, Hercules, CA, USA) at 20 µg/mL, P-Selectin was labeled with
AF647 anti-human CD62P (BioLegend, San Diego, CA, USA) at 2 µg/mL. AF647-conjugated
fibrinogen was added to whole blood at 12.5 µg/mL to observe fibrin formation.
Microfluidic devices were fabricated out of polydimethylsiloxane (PDMS, Ellsworth
Adhesives, WI, USA) using previously described soft lithography techniques (58). A single
channel (250 µm wide and 60 µm high) patterning device was vacuum-sealed to a Sigmacote®
(Sigma) treated slide. 5 µL of 1 mg/mL type I fibrillar collagen was perfused through the channel
to create a pro-thrombotic surface. For some experiments, 5 µL of 20 µM lipidated tissue factor
(TF, Siemens, Malvern, PA, USA) was adsorbed to the collagen surface through Dade Innovin PT
reagent. The TF was incubated for 30 minutes without flow and then rinsed with 20 µL of 0.5%
bovine serum albumin (BSA, Sigma) in Hepes-buffered saline (HBS, Figure 2-1). A microfluidic
device comprised of 8 parallel 250 µm wide channels with heights of either 60 µm or 120 µm
measured with a KLA Tencor P7 2 Profilometer (KLA Tencor, Milpitas, CA, USA) were positioned
perpendicular to the collagen strip and vacuum sealed to the slide. The device was incubated
with 0.5% BSA for 30 minutes prior to the introduction of blood.
CTI treated WB was perfused for a period of 180 sec through the 8-channel device within
10 minutes of phlebotomy (Figure 2-1B). An initial wall shear rate of 100 s-1 (24 µL/min) was set
by a syringe pump (Harvard PHD 2000, Harvard Apparatus, Holliston, MA, USA). After 3 minutes,
the WB was swapped out for HBS, and the wall shear rate was either held constant or increased
to 1000 s-1 (240 µL/min, Figure 2-1C). Wall shear rates were determined with COMSOL
Multiphysics (COMSOL Inc, Burlington, MA, USA). Platelets, fibrin, and P-Selectin were detected
by an epifluorescent microscope (IX81, Olympus America Inc, Center Valley, PA, USA) and a
charge-coupled device camera (Hamamatsu, Bridgewater, NJ, USA). Images were analyzed with
ImageJ (National Institutes of Health) with background-corrected mean fluorescence taken from
the middle 75% of the channel (Supplemental Figure I). Statistical analysis was done with
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GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA) and graphs were produced with
MATLAB (MathWorks, Natick, MA, USA). Data were compared between conditions using an
unpaired t-test. Data are presented as mean ± SD; p< 0.05 was considered significant.
Confocal microscopy was performed using a Leica TCS SP8 Confocal microscope (Leica
Camera, Wetzlar, GER). To utilize the available setup, thrombi were fixed prior to imaging. A
schematic of the fixing procedure is shown in Supplemental Figure II. Clots were first fixed before
shear by perfusing WB for 3 minutes followed by 3 minutes perfusion with BSA. Then, 2,4paraformaldehyde (Sigma) was perfused through the channels for 3 minutes. At the same time, a
second device followed the typical shear experimental design. After the shear period was over,
BSA was first perfused for 3 minutes followed by paraformaldehyde perfusion for 3 minutes. Clots
were than imaged in the 8-channel device with z-slices every 2.41 microns.

Figure 2-1: Procedure to investigate clot stability and morphology
(A) Collagen ± TF is patterned on a treated glass slide using a single channel device on a treated
glass slide. An 8-channel device is placed perpendicular to the collagen strip. Whole blood is
taken from healthy donors and added to the wells of the 8 channels, and a syringe attached to a
pump is added to the outlet port. (B) Clots are grown over the thrombotic surfaces to allow an
accumulation of platelets. (C) Blood is switched out for buffer and the flow rate is increased to
observe how the platelets decay over time.
11

Figure 2-2: A taller microfluidic device increases occlusion time which widens the window
to probe clot morphology and stability.
A taller microfluidic device increases occlusion time which widens the window to probe clot
morphology and stability. (A) Schematic demonstrating that 60 µm tall channels occlude when
switching to buffer (HBS) at an increased initial wall shear of 1000 s-1. High CTI WB was perfused
over a collagen/TF surface for 60 and 120 µm heights. (B) Platelets were labeled with AF488
anti-CD61. (C) Fibrin was examined by adding AF647-conjugated fibrinogen to the blood. (D). PSelectin expression was labeled with PE anti-CD62P. N = 8 clots for 1 donor.
2.1.3 Results
Previously, a 60 µm high 8-channel device had been used to investigate platelet function
and coagulation in whole blood (34,53,56,82). This height allows for ~500 sec to investigate
clotting under a constant flow regime but can lead to issues when switching to HBS to probe
thrombus stability. Due to a large influx of platelets when the flow rate is increased, a thrombus
can reach occlusion and embolize very quickly (Figure 2-2A). The clot then embolizes, and it is
difficult to continue the experiment. Due to donor-donor variation, occlusion is also variable
(Supplemental Figure III), and the lower height limits the robustness of a shear-based stability
assay. To remedy this, an extended height (120 µm) 8-channel device was fabricated with the
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same 250 µm width. When compared to the 60 µm height, the occlusion time increased 3-fold
(~500 s versus ~1500 s) for clots formed over collagen/TF surfaces (Figure 2-2B-D). The longer
occlusion time allows for the probing of thrombus stability without the possibility of embolism
during the switch to buffer.
With a repeatable approach for utilizing buffer perfusion to explore clot erosion, the effect
of increased shear rates was examined. High CTI WB was perfused over either collagen (Figure
2-3A, C) or collagen/TF (Figure 2-3B, D) at 100 s-1 initial wall shear rate followed by switching to
HBS (indicated by Δ) at the same initial shear rate (red/black) or increasing to 1000 s-1 (blue/light
gray). There were no differences in platelet fluorescent intensity between TF and no TF
conditions for both 100 s-1 (p = 0.807) and 1000 s-1 (p = 0.805) during the growth period. A higher
shear rate resulted in less platelets remaining in both the presence and absence of TF and
therefore thrombin. Within +TF and no TF conditions, increasing the shear rate of the buffer
significantly decreased the number of platelets (Figure 2-4A, p< 0.0001). The inclusion of TF on
the collagen surface increased the number of platelets left at both low shear rates (93 % vs 89 %,
p< 0.05) and high shear rates (84 % vs 70 %, p< 0.001). The fluorescent intensity of P-selectin
was measured for both conditions (Figure 2-4B). TF significantly increased P-selectin positive
platelets compared to no TF (p< 0.0001). There was no difference between 100 s-1 and 1000 s-1
conditions since their growth conditions were identical. These results suggest that thrombin plays
an important role in stability through the activation of platelets, and higher shear rates caused
greater erosion, as expected.
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Figure 2-3: Perfusion of buffer over thrombi allows for the probing of stability and
morphology in a shear dependent manner
High CTI WB at 100 s-1 was perfused over collagen or collagen/TF followed by switching to HBS
(Δ) at either an initial shear rate of 100 s-1 (red) or 1000 s-1 (blue). (A, B) Normalized platelet
fluorescent intensity (FI) calculated by normalizing to the highest intensity obtained during the
experiment. Data are expressed as mean ± SD with n=12 clots for 2 donors. (C, D)
Representative image of platelets in red at 3 minutes and 20 minutes. Scale bars are 100 µm.
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Figure 2-4: Tissue factor significantly increases clot stability and number of highly
activated platelets at both low and high shear rates when absorbed to the collagen surface
Fraction of platelets left after 20 minutes for growth and shear conditions described in Fig 1. (B)
P-Selectin FI after switching to buffer at 3 minutes for conditions described in Fig 1. Data are
presented as mean ± SD with n=12 clots for 2 donors. *: p < 0.05. **: p < 0.01. ***: p< 0.0001.
****: p< 0.0001.
To further examine the role of thrombin on stability, either PPACK (100 µM – red/dark
gray) to inhibit thrombin or GPRP (5 mM – blue/light gray) to inhibit fibrin but not thrombin was
added to high CTI WB for the growth period with a switch to buffer and increase in shear
occurring at 180 sec. For all conditions, platelet fluorescent intensities were the same at the end
of the growth period (p = 0.108 for GPRP vs PPACK, p = 0.197 for Control vs PPACK, p = 0.650
for Control vs GPRP). The inhibition of thrombin production resulted in fewer platelets remaining
15

at the end of the experiment when compared to both the control condition and GPRP condition
(p< 0.0001, Figure 2-5A, 2-6A) which agrees with the data in Figure 2-4. When thrombin but not
fibrin was present, the same number of platelets were left in comparison to the control (p =
0.791). This suggests that fibrin may not play a significant role in stability in this assay and that
fibrin resides in the core which is always shear resistant. Even though the overall platelet intensity
decreased when subjected to buffer, P-selectin fluorescent intensity did not. This suggests highly
activated P-selectin positive platelets are more stable than less activated P-selectin negative
platelets. P-selectin fluorescent intensity is significantly different between each of the three
conditions (p< 0.0001, Figure 2-6B). Both PPACK and GPRP inhibit all fibrin formation at the
concentrations used whereas fibrin is present in the control condition (Figure 2-6C). Overall,
these data demonstrate that the core region of a thrombus is stable when subjected to increased
shear. Thrombin is a key activator of platelets and the decreased stability in the PPACK condition
that lowering P-selectin intensity can lead to more platelet erosion.
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Figure 2-5: Thrombin inhibition, but not fibrin inhibition, decreases overall thrombus
stability while the core remains stable under all conditions
High CTI WB (±GPRP/PPACK) was perfused over collagen/TF at 100 s-1 followed by HBS at
1000 s-1 (Δ). (A) Normalized platelet FI of PPACK condition (red), GPRP condition (blue), and
control (green) normalized to the FI at 3 minutes. (B) P-Selectin FI for blood treated with PPACK
(red), GPRP (blue), or untreated (red) labeled with AF647 anti-CD62P. Data are expressed as
mean ± SD with n≥12 clots for 3 donors for each condition. (C) Representative images of clots at
3 minutes and 20 minutes with platelets in red, P-Selectin positive platelets in cyan, and
overlapping region in white. Scale bar is 100 µm.
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Figure 2-6: Inhibiting thrombin production decreases the number of platelets left at the
end of the experiment by limiting core size
(A) Fraction of platelets left after 20 minutes for growth and shear conditions described in Fig 4.
(B) P-selectin FI at 3 minutes for conditions described in Fig 4. (C) Fibrin FI at 3 minutes for
conditions described in Fig 4. Data are presented as mean ± SD with n≥12 clots for 3 donors. *: p
< 0.05. **: p < 0.01. ***: p< 0.0001. ****: p< 0.0001.
To further examine the stability of the shell region, ASA (50 µM - red) was added to
PPACK WB and incubated for 10 minutes prior to perfusion. ASA irreversibly blocks the formation
of thromboxane A2 (TxA2). During the growth period, ASA limited P-selectin positive platelets (p<
0.001), but not total number of platelets (p = 0.352, Figure 2-7A, B). When subjected to increased
shear and buffer, the ASA-treated thrombus eroded more than the control condition. At the end of
the experiment, only 40 % of the clot that was treated with ASA remained versus 65 % of the
control condition (p< 0.001, Figure 2-7A). However, P-selectin positive platelets did not erode
during the shear period (Figure 2-7B). This further supports that the core region is stable when
subjected to high shear rates.
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Figure 2-7: Aspirin lowered initial platelet deposition and decreased the stability of shell
platelets when subjected to shear
. PPACK WB ± 50 µM ASA incubated for 5 minutes prior to perfusion was perfused over
collagen/TF at 100 s-1 followed by HBS at 1000 s-1 (Δ). (A) Normalized platelet FI normalized for
aspirin treated blood (red) and control condition (blue). (B) P-Selectin FI for blood treated with
aspirin (red) or not treated (blue). Data are expressed as mean ± SD with n=11 clots for 3 donors.
(C) Representative images of clots with platelets in red and P-Selectin positive platelets in cyan.
Scale bar is 100 µm
To inhibit ADP responses, MRS-2179 (100 µM - red) was added to PPACK WB to
antagonize P2Y1 and prevent ADP binding. P2Y1 antagonism lowers both platelets and Pselectin positive platelets during the growth period similarly to TxA2 inhibition (Figure 2-8A, B, p<
0.001). After switching to buffer, the MRS-2179 treated platelets were more likely to come off the
thrombus compared to the control, with P-Selectin positive platelets being stable in both
conditions.
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Figure 2-8: A P2Y1 inhibitor lowered initial platelet deposition and decreased stability of
shell platelets when subjected to shear
PPACK WB ± 100 µM MRS-2179 was perfused over collagen/TF at 100 s-1 followed by HBS at
1000 s-1 (Δ). (A) Normalized platelet FI for treated blood (red) and control condition (blue). (B) PSelectin FI for treated blood (red) or not treated (blue). Data are expressed as mean ± SD with
n=12 clots for 3 donors. (C) Representative images of clots with platelets in red and P-selectin
positive platelets in cyan. Scale bar is 100 µm.
To examine the other main integrin involved in ADP activation of platelets, 2-MeSAMP
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(100 µM - red) was added to PPACK WB to antagonize P2Y12 and prevent ADP binding. P2Y12
antagonism lowers both platelets and P-selectin positive platelets during the growth period
significantly during the growth period (Figure 2-9A, B, p< 0.001). After switching to buffer, the 2MeSAMP treated platelets were more likely to come off the thrombus compared to the control,
with P-Selectin positive platelets being stable in both conditions.

Figure 2-9: A P2Y12 inhibitor lowered initial platelet deposition and decreased stability of
shell platelets when subjected to shear
PPACK WB ± 100 2-MeSAMP was perfused over collagen/TF at 100 s-1 followed by HBS at 1000
s-1 (Δ). (A) Normalized platelet FI for treated blood (red) and control condition (blue). (B) PSelectin FI for treated blood (red) or not treated (blue). Data are expressed as mean ± SD with
n=12 clots for 3 donors. (C) Representative images of clots with platelets in red and P-selectin
positive platelets in cyan. Scale bar is 100 µm.
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Side view images of clots before and after shear were obtained using confocal
microscopy and are shown in Figure 2-10. After three minutes of growth in each device,
fluorescence intensities were not statistically significant from each other. The top row shows clots
that were not subject to shear, and the bottom row shows clots that were subjected to shear. The
two clots in the right column were not treated with anything, and the two on the left were treated
with PPACK. The images show a clear core/shell hierarchy with a P-selectin (+) core (blue)
surrounded by a P-selectin (-) shell. Additionally, fibrin (purple) is only present close to the
collagen surface in the core region. By looking at the FI in the middle 75% of the clot for each zslice, the approximate height of each clot could be determined. By measuring these values for all
the conditions in each device (N = 1 donor, 4 clots), a change in height for both the core and shell
regions was determined. The platelet FI data indicated that the overall height of the clot
decreased by 4.06 ± 1.98 μm in the control condition and 13.66 ± 2.51 μm for the PPACK
condition. The core region, measured by P-selectin FI, decreased by 0.65 μm for both conditions,
a negligible change in core height.

Figure 2-10: Confocal images show clear core/shell morphology
Images were taken of clots treated with or without PPACK formed over collagen/TF before and
after shear with confocal microscopy. These images show a P-selectin positive core region (blue)
with fibrin co-localized in the core (purple) surrounded by a P-selectin negative shell (green). This
morphology is seen with or without thrombin present, with a clear reduction in core size and a
larger rate of platelet decay with PPACK present.
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2.1.4 Discussion
To study the contribution of the spatiotemporal heterogeneity of clotting mechanisms to
thrombus stability, we developed a two-part microfluidic assay that utilizes an extended height 8channel device. CFB simulations indicate a relatively uniform shear rate for this geometry
(Supplemental Fig. III). This is further demonstrated by the similarity of thrombus growth
dynamics when compared to the 60 µm height prior to occlusion. By increasing the channel
height of the 8-channel and adjusting the flow rates to preserve dynamics, the modified device
allows for a longer time period to study thrombus morphology and stability. While not utilized in
this study, the extended height 8-channel is capable of growing large clots, at least as long as 6
minutes, and then switching to buffer with no embolism or occlusion occurring (Supplemental
Figure IV).
As clot formation proceeds, there is a temporal distribution of various agonists. Early on,
thrombin and collagen drive platelet activation and clot, and at later time points, secondary
agonists ADP and TxA2 play a larger role. One of the key benefits of this assay is that swapping
in buffer stops coagulation and platelet deposition and allows for probing of the structure of the
clot at a particular time point.
Previous research has shown that fibrin plays a key role in governing stability (77), but clots
formed in the presence of GPRP to block fibrin formation were as stable as clots formed without
GPRP present in this assay. Since the P-selectin signal was constant, core platelets did not
erode and therefore only shell platelets were affected by shear. This suggests that fibrin is only
present in the core. Furthermore, inhibition of thrombin decreased P-selectin fluorescent intensity
and led to more platelet erosion most likely due to less overall platelet activation. GPRP
increased P-selectin fluorescent intensity most likely as a result of larger thrombin generation
(54,61). However, platelet erosion was not affected suggesting that more than just P-selectin
expression governs stability. These findings were confirmed with the confocal images shown in
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Figure 2-10. Fibrin is only present in the core region, and since that region is stable, it had no
effect on stability in this assay. Furthermore, the core region was approximately the same height
before and after shear for both control blood and blood treated with PPACK.
The core/shell model suggests that outside of the P-selectin positive region, very little to no
thrombin is present. In this outer region, ADP and TxA2 regulate platelet activation once they are
produced by platelets resulting in secondary activation. The data with secondary agonist
inhibitors further supports this conclusion. Secondary agonists contribute somewhat to core
formation and α-granule release but not as significantly as thrombin. All three inhibitors lowered
P-selectin expression further supporting that less P-selectin leads to more platelet erosion.
However, aspirin did not significantly affect total platelet fluorescent intensity whereas MRS-2179
and 2-MeSAMP did. Even though the fraction of platelets left for both ASA and MRS-2179
conditions are similar, aspirin treated blood had more initial platelet deposition and therefore more
platelets eroded. This suggests that TxA2 production plays a crucial role in stabilizing shell
platelets and P2Y1 may be more important for initial platelet aggregation. 2-MeSAMP treated
blood had the most significant effect on both initial platelet aggregation and clot stability. This
suggest that P2Y12 signaling is vital for any sustained clot formation and removing this pathway
might result in other secondary agonist signals to not be amplified enough to produce sufficiently
activated platelets to resist shear. Overall, secondary agonists help stabilize platelets in the shell
region that are more likely to be sheared off.
In summary, we demonstrate a new two-part microfluidic assay utilizing an extended height
8-channel microfluidic device that allows for precise control of thrombus growth conditions
followed by increases shear rates to examine stability and morphology.
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CHAPTER 3 – WHOLE BLOOD MICROFLUIDICS TO ASSESS DIRECT ORAL
ANTICOAGULANTS (DOACs) ACTIVITY AND REVERSAL IN NEONATAL CARDIAC
PATIENTS
3.1 Ex vivo apixaban lowers thrombotic activity in neonatal cardiac patients to a higher
degree than adults

3.1.1 Introduction
According to the CDC, congenital heart disease (CHD) affects nearly 1%, or 40,000,
births per year in the United States (83,84). Of those, approximately 1 out of 4 cases are defined
as critical CHD which require surgery or other procedures within a few weeks of birth.
Thromboembolic events that occur as a result of these palliative surgeries remain a significant
cause of mortality and morbidity (85,86). To remedy this, aspirin prophylaxis often occurs a few
hours after surgery, but thrombosis can occur shortly after surgery before this procedure happens
(87,88). Unfractionated heparin is another commonly used anticoagulant, yet it appears to be
ineffective at preventing shunt thrombosis (89–91).
Despite the plethora of approved direct oral anticoagulants (DOACs) by the FDA for use
in adults at high risk of cardiovascular events, there are no currently approved drugs for use in
neonates due to a lack of information regarding dosing and efficacy (92,93). Therefore, many
drugs are used in an off-label fashion where there are dire circumstances for not properly
balancing the prevention of thrombosis with the risk of bleeding (94). There are currently a
number of DOACs approved for use in adults: four that are factor Xa inhibitors (apixaban,
edoxaban, ebtrixabran, rivaroxaban) and one that is a direct thrombin inhibitor (dabigatran) (95).
In particular, apixaban is appealing due to its lack of dependency on antithrombin and its low
bleeding rates in adults (96,97). There are no current or completed studies on the effects of
apixaban in neonates with congenital heart disease (96). Factor Xa inhibitors also have a
commercially available, FDA approved, reversal agent, andexanet alfa. Andexanet alfa is a
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recombinant form of FXa that is catalytically inactive through the loss of a Gla domain; yet it
retains a high affinity active site that will bind to DOACs in a 1:1 stoichiometric ratio. Andexanet
binds and sequesters FXa inhibitors and restores the activity of endogenous FXa (98–101).
Significant differences between the neonate and the adult hemostatic system have been
previously studied (102–105). The hemostatic system changes and matures throughout life until
adulthood is reached. It has been found that a number of coagulation factors are lower for the first
year of life resulting in decreased coagulation potential (106). Neonatal platelets have also been
found to have reduced responses to a number of different agonists, such as thrombin receptor
activator peptide-6 (TRAP), ADP, and collagen-related peptide (CRP) (107,108). However, these
conclusions are often drawn from cord blood or from assays that do have proper hemodynamics.
Additionally, assays need to be adept at drawing meaningful conclusions from small amounts of
blood. Therefore, there exists a need for better assays to examine how the neonatal hemostatic
system varies from adults and furthermore, how anticoagulants may respond differently in this
population when compared to adults. To address this need, we utilize an 8-channel microfluidic
device that has been shown to be sensitive to neonatal platelets to test the efficacy of apixaban in
neonates with CHD before and after surgery. This assay is able to generate large amounts of
data from less than 1 mL of blood and accurately replicates conditions found within the body.

3.1.2 Materials and Methods
Patients with CHD consisting of primarily double ventricle physiology requiring palliative
bypass shortly after birth were enrolled in the study by Dr. Thomas Diacovo of the University of
Pittsburgh Medical Center. Patients often required blood products after surgery, and there was no
difference in hemoglobin and hematocrit (Hb / Hct), platelet count, or fibrinogen levels pre- vs
post-surgery. There are 25 total patients in the study, with 18 of them being used in this first
apixaban study.
1 mL of whole blood (WB) was collected in 40 µg/mL corn trypsin inhibitor (CTI,
Haematologic Technologies, Essex Junction, VT, USA) from either the recruited patient
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population or from healthy adult donors who self-reported to be free of oral medication for at least
7 days prior to blood draw. The WB was then mixed with varying concentrations of apixaban
(Bristol Myers Squibb, New York, NY, USA). Platelets were labeled with an AF488 mouse antihuman CD61 antibody (Bio-Rad Laboratories, Hercules, CA, USA) at 20 µg/mL, and fibrin
formation was monitored with the addition of 12.5 µg/mL AF647-conjugated fibrinogen
(ThermoFisher Scientific, Waltham, MA, USA).
A single channel (250 µm wide) polydimethylsiloxane (PDMS) device was vacuumedsealed to a Sigmacote (Sigma-Aldrich, St Louis, MO, USA) treated glass slide. 5 µL of .75 mg/mL
type I fibrillar collagen (Chrono-log, Havertown, PA, USA) was drawn through the channel
followed by a 30-minute incubation of 5 µL of 13 µM lipidated tissue factor (TF; Siemens, Munich,
Germany) which resulted in adsorption in the collagen surface. The channel was then rinsed with
20 µL of 0.5% bovine serum albumin (BSA; Sigma-Aldrich) in 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid–buffered saline (HBS). A PDMS microfluidic device comprised of
8-parallel 250 µm wide and 60 µm wide channels was vacuum sealed perpendicular to the
collagen surface. The device was incubated with 0.5% BSA for 30 minutes prior to blood
perfusion. The apixaban treated WB was perfused through the 8-channel device at an initial wall
shear rate of 200 s-1 set by a syringe pump (PHD 2000; Harvard Apparatus, Holliston, MA, USA).
The WB was perfused until either occlusion of the channels occurred, or 15 minutes had
passed. Each experiment comprised of 3 identical devices ran in parallel with each device having
2 channels of 0 µM, 0.25 µM, 0.5 µM, and 1 µM apixaban. Images were collected using
fluorescent microcopy and were analyzed with ImageJ (National Institutes of Health, Bethesda,
MD, USA). Background corrected mean fluorescence was calculated from the middle 75% of the
channel. Statistical analysis was conducted with Prism 9 (GraphPad Software, La Jolla, CA, USA)
with statistical significance calculated using Mann-Whitney U tests. Data are presented as mean
± SD and p < 0.05 was considered significant.
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3.1.3 Results
Neonatal blood thrombotic activity before and after surgery was compared to adults
without apixaban to establish baselines. Representative images of both platelet and fibrin
deposition of healthy adults, neonates before surgery (pre-op), and neonates after surgery (postop) are shown in Fig. 3-1A. Average platelet (Fig. 3-1B) and fibrin (Fig. 3-1C) fluorescent intensity
(FI) was calculated and graphed up to five minutes. Five minutes was chosen as a cutoff point
since no donors had occluded at 5 minutes. Prior to surgery, neonatal blood had significantly
lower platelet and fibrin activity (p < 0.0001) than both post-op and adult blood for minutes 3-5.
There was no statistical significance between post-op neonatal blood and adult platelet FI for all
time points. However, post-op blood had significantly lower fibrin activity for minutes 4 and 5
when compared to healthy adult blood (p < 0.01). Occlusion time (Fig. 3-1D) for each donor is
determined as the point where the clot reaches the top of the channel. Pre-op blood has a
significantly longer occlusion time (p < 0.0001) than both adults and post-op blood, and there was
no difference between adults and the post-op condition (p = 0.057).
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Figure 3-1: Thrombotic activity of healthy adults and at-risk neonates
A, Representative images of fibrin and platelet deposition for adults and the patient population
before (Pre-op) and 24h after surgery (Post-op). Mean platelet (B) and fibrin (C) fluorescence
intensities were monitored at 1-minute intervals prior to thrombus occlusion. Occlusion time (D)
was defined as the point where the thrombus has reached the top of microfluidic channel with a
value of 15 minutes being assigned if no occlusion is reached. Statistical significance was
determined using Mann-Whitney U test. *: p <0.001. Adults: N = 9, n = 50. Pre-op: N = 18,
n
= 112. Post-op N = 18, n = 98.
After surgery, neonatal blood is on average more thrombotically active than prior to
surgery as demonstrated by the results in Fig. 3-1, but there is a degree of heterogeneity in the
patient population when it comes to changes in occlusion time (Fig. 3-2A), platelet activity (Fig. 32B), and fibrin activity (Fig. 3-2C). 15 out of the 18 patients had an increase in platelets and 16
out of the 18 patients saw decreased occlusion time. A much smaller portion of the patient
population saw increases in fibrin activity, only 6 out of 18. This data shows that while on average
neonates have increased thrombotic activity, the patient population is heterogenous which most
likely results from different clinical phenotypes and surgeries.
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Figure 3-2: Patient population before and after surgery
A, Occlusion time (minutes) of each patient before and after surgery. B, Platelet fluorescence
intensity at 5 minutes before and after surgery for each patient. C, Fibrin fluorescence intensity at
5 minutes before and after surgery for each patient. Statistical significance was determined using
Mann-Whitney U test. *: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001. n ≥ 6 for each
patient.
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Prostaglandin E1 (PGE1) is used to neonates with ductal-dependent cardiac lesions to
keep ductus arteriosus patent prior to surgery (109). It can potentially be lifesaving, and the
effects of this treatment on pre-op platelet activity (Fig. 3-3A), fibrin activity (Fig 3-3B), and
occlusion time (Fig. 3-3C) are shown in Figure 3-3. 12 patients received PGE1 treatment, and 16
of them did not. There was no significant difference in either platelet activity or occlusion time,
and a minor reduction (p < 0.01) in fibrin activity.

Figure 3-3: Prostaglandin treatment prior to surgery
A, Thrombotic activity of neonatal cardiac patients with or without prostaglandin treatment prior to
surgery in response to immobilized collagen/TF surfaces using a multi-well microfluidic device.
Mean platelet (A) and fibrin (B) FI were monitored at 1-minute intervals prior to thrombus
occlusion. Occlusion time (C) was determined by the thrombus reaching the top of the
microfluidic channel and was given a value of 15 minutes if no occlusion is reached. Statistical
significance was determined using Mann-Whitney U test. *: p < 0.01. (+) Prostaglandins: N = 12,
n = 64. (-) Prostaglandins: N = 16, n = 85.
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The effects of ex vivo apixaban on platelet and fibrin activity in healthy adults and
neonates pre- and post- surgery are shown in Figure 3-4. Row 1, in blue, shows platelet values
whereas row 2, in red, graphs fibrin values. All values are normalized for each donor to the
control condition at 5 minutes. 5 minutes is chosen since no donors had occluded by this time
point. For almost every condition and every donor, apixaban significantly lowered platelet and
fibrin activity (p < 0.0001) when compared to blood without apixaban. The only apixaban
concentration that did not have a statistically significant difference from the control platelet activity
with 0.25 µM apixaban. These data show that apixaban is a powerful anti-thrombotic drug
capable of drastically lowering platelet and fibrin activity in both adults and neonates, and this 8channel microfluidic device is capable of generating large amounts of data that is sensitive to
apixaban from a small volume of blood.

Figure 3-4: The effect of apixaban on platelet and fibrin deposition
Normalized platelet (blue) and fibrin (red) fluorescence intensities for both healthy adults and atrisk neonates. FIs are normalized to the control condition for each donor individually. Significance
was determined using Mann-Whitney U test. ****: p < 0.0001. Adults: N = 9, n = 50. Pre-op: N =
18, n = 112. Post-op: N = 18, n = 98.
Representative images of the effect of ex vivo apixaban for adults and neonates before
and after surgery are shown in Figure 3-5A. To further examine the efficacy of apixaban,
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occlusion times were determined for each donor before and after surgery and shown in Figure 35C. For healthy adults and neonates prior to surgery, while apixaban had a significant effect on
both platelet and fibrin activity, there was no significant increase in occlusion time with apixaban
present. However, apixaban significantly prolonged occlusion time in neonatal patients postsurgery for all apixaban concentrations (p < 0.0001). The higher potency of ex vivo apixaban in
post-op patients is further illustrated in Figure 3-5C. At both 0.25 µM (p = 0.0044) and 0.5 µM (p =
0.034) apixaban, post-op blood had significantly lower platelet activity compared to adults at the
same concentrations. This data shows that apixaban is more effective at limiting platelet activity
and prolonging occlusion time in neonates after surgery than adults.

Figure 3-5: The effect of apixaban on thrombotic activity and occlusion time
Neonatal blood post-surgery is most sensitive to apixaban than adult blood. Representative
images of the effects of apixaban for adults and neonates before and after surgery. Normalized
fibrin and platelet FI (B) for adults and post op at 5 minutes. Occlusion time (C) was determined
by the thrombus reaching the top of the microfluidic channel and was given a value of 15 minutes
if no occlusion is reached. Statistical significance was determined using Mann-Whitney U test. *:
p < 0.0001. Adults: N = 9, n = 50. Pre-op N = 18, n = 112. Post-op N = 18, n = 98.
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3.1.4 Discussion
By examining platelet FI, fibrin FI, and occlusion time for conditions without apixaban, we
determined that there is drastically different thrombotic activity before and after surgery. Prior to
surgery, thrombotic activity is extremely low over highly thrombotic collagen + tissue factor
surfaces; this result is consistent with other recent results that show that neonatal blood reacts
less strongly to a number of different agonists. This result further supports that early on in
development hemostasis, neonatal blood is less responsive. After surgery, we observed
thrombotic activity that is very similar to healthy adult patients. One possible explanation for this is
neonates are given adult blood products which this assay shows to be more active than neonatal
blood prior to surgery. This data also reinforces that this patient population is at an increased
thrombotic risk after surgery. This shows the need for a better understanding of this patient
population’s thrombotic profile after surgery to better inform treatments. Even though we
observed a large range of increased thrombotic activity after surgery, there was still on average a
very strong increase in activity, particularly in platelets.
We utilized three different apixaban concentrations to test both the sensitivity of the
microfluidic device to apixaban and the patients’ blood response to the apixaban. We observed a
significant reduction in fibrin activity in all three data sets with only 0.25 µM apixaban present,
which demonstrated that an 8-channel microfluidic device is capable of capturing the effects of
apixaban, even at low concentrations. The device setup also allows for 24 simultaneous
conditions with less than 1 mL of blood used. We observed that the patient population
demonstrated a large degree of sensitivity to apixaban via significant reduction in both platelet
and fibrin activity. Interestingly, we observed that neonatal platelets after surgery were more
sensitive than adult blood which contributed to a prolonged occlusion time. One observed effect
of development hemostasis is lower factor X and factor V concentrations in the blood. This results
in decreased coagulation potential. With less potential for thrombin production, apixaban can be
more effective at limiting thrombin production. With less thrombin produced and noted
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insensitivity to many agonists, apixaban can severely affect the extent of platelet activation in
post-op neonates.
We have demonstrated that an 8-channel microfluidic is capable of capturing the effects
of ex vivo apixaban on both platelet and fibrin activity in healthy adults and an at-risk neonate
population. Furthermore, we demonstrated that apixaban is capable of limiting the large increase
in thrombotic activity observed post-surgery in neonates and may be suitable as a possible
treatment with further study in the future.
3.2 Andexanet alfa restores coagulation activity lowered by apixaban in both adults and
neonates

3.2.1 Materials and Methods
The same patient population of 23 patients previously described was used for this study
on the effect of andexanet alfa. 5 of the 23 patients were utilized with the following microfluidic
design. 1 mL of WB was collected in 40 µg/mL CTI from either the recruited patient population or
from healthy adult donors who self-reported to be free of oral medication for at least 7 days prior
to blood draw. The WB was then mixed with varying concentrations of apixaban or 50 µg/mL
andexanet alfa. Platelets were labeled with an AF488 mouse anti-human CD61 antibody at 20
µg/mL, and fibrin formation was monitored with the addition of 12.5 µg/mL AF647-conjugated
fibrinogen.
Device patterning was conducted as previously described. WB was perfused until either
occlusion of the channels occurred or 15 minutes had passed. Each experiment comprised of 3
identical devices ran in parallel. Each device comprised of 6 different conditions: a control with no
apixaban or andexanet, a 0.5 µM apixaban control, a 50 µg/mL andexanet control, one channel
with 0.1 µM apixaban and andexanet, and 2 channels each of 0.25 µM apixaban and 0.5 µM
apixaban with 50 µg/mL andexanet. To replicate the use of andexanet alfa as a reversal agent
with apixaban already present, the WB was first mixed with apixaban and the andexanet was
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secondarily added. Images were collected using fluorescent microcopy and were analyzed with
ImageJ. Background corrected mean fluorescence was calculated from the middle 75% of the
channel. Statistical analysis was conducted with Prism 9 with statistical significance calculated
using Mann-Whitney U tests. Data are presented as mean ± SD and p < 0.05 was considered
significant.

3.2.2 Results
0 – 100 µg/mL andexanet alfa was tested in healthy adults without any apixaban present
to see if there was any effect on thrombotic activity. Fluorescence intensities were normalized to
the control condition for each donor at 5 minutes to calculate a normalized percent deposition.
There was no observed effect on platelet (Fig. 3-6A) or fibrin (Fig. 3-6A) at 25 or 50 µg/mL
andexanet, but there was a significant decrease in platelets (p < 0.01) and fibrin (p < 0.001) at
100 µg/mL. To avoid this complication, a concentration of 50 µg/mL will be used for the rest of the

Figure 3-6: The effect of andexanet alfa on healthy adults
A, Platelet fluorescence intensity normalized at 5 minutes to the control condition for each donor.
B, Fibrin FI normalized at 5 minutes to the control condition for each donor. Statistical significance
was determined using Mann-Whitney U test. **: p < 0.01, ***: p < 0.001. N = 4, n = 24.
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experiments.
To examine if andexanet will reverse the effects of ex vivo apixaban in the microfluidic
device in healthy adults, apixaban was first added to WB and then the andexanet was added after
the fact. For 5 out of the 6 conditions outlined in the materials section, normalized deposition for
platelets and fibrin are shown in Fig. 3-7. For platelet FI (Fig. 3-7A), there was no statistical
significance in any of the tested conditions. For fibrin activity (Fig. 3-7B), 0.5 µM apixaban
significantly lowered deposition (p <0.0001), whereas 50 µg/mL andexanet + 0.5 µM apixaban did
not have a significantly lower fibrin deposition compared to the control (p = 0.543). This illustrates
that andexanet alfa is capable of reversing the inhibition of apixaban.

Figure 3-7: Andexanet alfa is capable of reversing the effects of apixaban
A, Platelet fluorescence intensity normalized at 5 minutes to the control condition for each donor.
B, Fibrin FI normalized at 5 minutes to the control condition for each donor. Statistical significance
was determined using Mann-Whitney U test. *: p < 0.05 **: p < 0.01, ****: p < 0.0001. N = 8, n =
23.
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Representative images of platelet and fibrin deposition in response to apixaban and
andexanet are shown in Figure 3-8A. To make sure that there was no thrombotic effect of
andexanet alfa, FI’s are normalized to the control condition for both platelets and fibrin. There
was no significant effect of andexanet on either platelet or fibrin for adults and neonates before
and after surgery.

Figure 3-8: Andexanet alfa has no effect on thrombotic activity at 50 µg/mL
Representative platelet and fibrin images of healthy adults and neonates before and after
surgery. The effect of 50 µg/mL andexanet alfa on normalized percent deposition at 5 minutes.
Statistical significance was determined using Mann-Whitney U test. Adults: N = 8, n ≥ 23. Postop: N = 5, n ≥ 12.
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Figure 3-9: Andexanet alfa restores platelet and fibrin activity in neonates after surgery
A, Platelet fluorescence intensity normalized at 5 minutes to the control condition for each donor.
B, Fibrin FI normalized at 5 minutes to the control condition for each donor. Statistical significance
was determined using Mann-Whitney U test. ****: p < 0.0001. N = 5, n ≥ 23.
The effects of andexanet alfa on neonatal blood after surgery are shown in Figure 3-9.
There was a significant reduction in normalized platelet (Fig. 3-9A) and fibrin (Fig. 3-9B)
deposition when 0.5 µM apixaban was added (p < 0.0001). This reduction was reversed when
andexanet alfa was mixed with any of the three apixaban concentrations resulting in there not
being a significant difference between those conditions and the control.

3.2.3 Discussion
With an established assay that is sensitive to apixaban shown in Chapter 3-1, we
examined the efficacy of andexanet alfa to ensure that apixaban can be reversed in an adverse
bleeding event in neonates. We first saw that very high concentrations of andexanet alfa have an
anti-thrombotic effect which has not been observed before. We did not want this conflicting effect
in our study in neonates, so we chose a concentration of 50 µg/mL for the rest of the studies. By
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testing different apixaban concentrations with a constant 50 µg/mL of andexanet, we observed
that having andexanet alfa reverses the effects of apixaban even when they were not in 1:1
stoichiometric concentration. Interestingly, neonatal blood was more sensitive to andexanet alfa
after surgery when compared to adults. This agrees with previous data that neonatal blood was
more sensitive to apixaban.
This data combined with data in Chapter 3-1 demonstrates apixaban and its reversal
agent are a viable therapeutic avenue for neonates with congenital heart disease. Extra care
needs to be taken when thinking of using apixaban in the future due to neonatal blood being more
sensitive to it than adult blood. We have also shown that a microfluidic device captures the
thrombotic effects of apixaban and its reversal agent and generates large amounts of data from
small volumes of blood.

40

CHAPTER 4 – FUTURE WORK
4.1 Core platelets of a thrombus resist contractile forces
Clot contraction is an important component of hemostasis where the clot is reduced in
size to prevent blood flow obstruction and prevent clot degradation from both mechanical and
chemical forces (110,111). Clot contraction is comprised of many different processes that act on
different components of the thrombus including extrusion of procoagulant platelets, redistribution
of fibrin and reduction in clot size (63,112–114). Platelet contraction occurs via non-muscle
myosin which has been shown via reduction in clot contraction through treatment with blebbistatin
and plays a key role in stabilizing clots (115). Many assays have been utilized to look at clot
contraction, but the conditions under which thrombi are formed tend to not be physiological (116).
Utilizing an 8-channel microfluidic device that has been shown to have similar hemodynamics to
those found within the human body, we aim to study contraction under physiological relevant
conditions.
To examine clot contraction, whole blood (WB) was collected in 40 µg/mL corn trypsin
inhibitor (CTI) from healthy donors who self-reported to be free of oral medication for at least 7
days prior to phlebotomy. All blood was collected under approval of the University of
Pennsylvania’s Institutional Review Board. Whole blood was treated with either 100 µM D-PhePro-Arg-CMK (PPACK) or 100 µM 2-Methylthioadenosine 5′-monophosphate triethylammonium
salt hydrate (2-MeSAMP, Sigma, St. Louis, Mo, USA). Platelets were labeled with an AF488
mouse anti-human CD61 antibody at 20 µg/mL, P-Selectin was labeled with AF647 anti-human
CD62P at 2 µg/mL.
Microfluidic devices were fabricated as described in Chapter 2.1.1. Collagen + tissue
factors were created in the same fashion as Chapter 2.1.1. A microfluidic device comprised of 8
parallel 250 µm wide channels with a height of 120 µm were positioned perpendicular to the
collagen strip and vacuum sealed to the slide. The device was incubated with 0.5% BSA for 30
minutes prior to the introduction of blood. CTI treated WB was perfused for a period of 7.5
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minutes through the 8-channel device within 10 minutes of phlebotomy. An initial wall shear rate
of 100 s-1 (24 µL/min) was set by a syringe pump, and after 7.5 minutes, flow was stopped. The
clot was then allowed to contract within the 8-channel device for an additional 7.5 minutes.
To quantify contraction, a percent contraction metric was developed. This procedure is
outlined in Supplemental Figure V. First, platelet or P-selectin images are binarized using
thresholding at 7.5 minutes. A threshold of half the average fluorescence of the clot was chosen.
Then, initial clot lengths are measured in the middle 100 pixels of the clot for both fluorophores in
the same direction as the flow of blood. This was done by utilizing MATLAB to find the top and
bottom most pixel in each of 100 x-positions centered at the middle of the clot. These were then
average to find an average clot length. The average clot length was calculated at both 7.5 and 15
minutes, and then these values were used to calculate the percentage change in clot length.
First, we looked at the fluorescence intensity curves for both platelets and P-selectin
(Figure 4-1A, B). We found that at 7.5 minutes of growth, there was no difference in total platelet
deposition between the control condition (Fibrin) and PPACK (p = 0.643). However, 2-MeSAMP
treatment drastically lowered total platelet deposition when compared to both the control and
PPACK conditions (p < 0.0001). Additionally, all three P-selectin values were significantly
different from each other (p < 0.0001). Utilizing the method described, percent contraction was
calculated for all three conditions. Representative images before and after contraction, and the
percent contraction lengths are shown in Figure 4-2. First comparing percent contractions
between control and PPACK conditions, when fibrin is present there is a much smaller degree of
contraction compared to a fibrin free system for the entire clot (8.77% versus 20.28%, p < 0.0001)
and also in the core region (2.54% vs 8.25%, p < 0.0001). This suggests that fibrin plays a role in
resisting clot contraction. Additionally, for both conditions, percent contraction of the P-selectin (+)
platelets, or the core region, is significantly lower (p < 0.0001). This shows that the core region
resists the contractile forces with or without fibrin present.
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Figure 4-1: PPACK lowers P-selectin expression and 2-MeSAMP lowers both total platelet
accumulation and P-selectin expression
A, Platelet FI for control blood (red) and blood treated with PPACK (blue) or PPACK + 2MeSAMP (green). B, P-selectin FI for control blood and blood treated with PPACK or PPACK + 2MeSAM. C, Representative images of each condition both and after contraction. Δ = cessation of
flow at 7.5 minutes.
Looking at the effects of 2-MeSAMP treated WB, there is not a significant difference in
the change in clot contraction for either the platelet or P-selectin FI (9.26% vs 8.50%, p = 0.367).
This suggests that P2Y12 antagonism severely limited the formation of a shell region. There was
also no difference between core contraction for the PPACK and 2-MeSAMP conditions (8.25% vs
8.50%, p = 0.898). Taken together, this data further confirms that there is core/shell hierarchy
present in thrombi grown in this 8-channel microfluidic device comprised of a highly activated and
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resistant core region surrounded by a less activated shell region that is susceptible to both shear
and contractile forces. Additionally, this data shows the P2Y12 signaling is vital for formation of a
stable shell region and also affects core size.

Figure 4-2: Core platelets of the thrombus resist contraction
Representative images of platelet (red) and P-selectin (cyan) contraction from 7.5 to 15 minutes.
Average percent contraction of each of the three conditions (Fibrin, PPACK, 2-MeSAMP) are
shown in the table
This data can be built off of and confirmed through a couple of different experiments.
Namely, confocal images of clots treated with PPACK and 2-MeSAMP taken before and after
both shear and contraction would give vital insight into clot morphology. We will be able to tell the
exact size of the core and shell regions when there is no P2Y12 signaling. Additionally, the
contraction and shear assays can be combined to better understand how contraction changes
how thrombi are resistant to shear. In short, clots can be grown, allowed to contract under
stagnant conditions, then the blood can be exchanged for buffer and the shear rate can be
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increased to examine platelet decay. This is easily achievable with the extended height device
that was designed. Growth times up to at least 6 minutes have been shown to not occlude when
changing to buffer (Supplemental Figure IV).
4.2 Incorporation of fluorescence beads into thrombi
To look at another metric of clot contraction, 1-micron FluoSpheres Polystyrene
Microsphere (yellow green) (ThermoFisher) were mixed with WB at a concentration of 2 x 108
beads/mL. The same contraction procedure and percent contraction protocol were followed that
are outlined in Chapter 4-1. Representative images of these beads are shown in Figure 4-3. For
the control condition, the beads displayed almost no change in percent contraction (0.90%)
whereas the PPACK condition demonstrated a 18.63% contraction. There were not enough
beads embedded in the 2-MeSAMP clots to get accurate measurements. Since this metric does
not provide much insight into the contraction process, particle tracking was done on the beads in
ImageJ. The built-in plugin detects individual beads and tracks their movement through each time
point. The positional data for each particle can then be processed to gain insight into clot
contraction. There is minor accumulation of beads once flow was stopped, so only particles that
are present in every time point are included in measurements. Representative images of particle
tracking are shown in Figure 4-4. By measuring the average movement of beads throughout the
clot, the particle tracking data showed that there was more contraction in the PPACK condition
(9.1 vs 4.3 microns, p < 0.001) and there was also significantly more movement in the
downstream half of the clot (20.5 vs 40.2 microns PPACK, p < 0.0001) and (5.0 vs 3.5 microns
Control, p < 0.01).
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Figure 4-3: Fluorescence beads are an indicator of contraction when there is no fibrin
present
Representative images of fluorescent beads before and after contraction for control, PPACK, and
PPACK + 2-MeSAMP conditions.
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Figure 4-4: Demonstration of particle tracking via ImageJ
This preliminary data demonstrates that is heterogenous clot contraction with a larger
degree of contraction occurring in the downstream portion of the clot. While interesting, this data
can be built upon in several ways. First, with position data from particle tracking, algorithms can
be developed that will create displacement vectors for each particle. This data can be utilized to
create 2-D strain fields which will further inform where clot contraction is occurring. Confocal
imaging can be done to see where exactly these beads are being embedded in clots. By
examining if the clots are primarily in the core or shell, or even distributed, the strain fields
calculated can give further insight into how core and shell platelets resist contractile forces.
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APPENDIX – SUPPLEMENTAL FIGURES

Supplemental Figure I: The 120 µm height channel has a slightly less uniform shear rate
than the 60 µm height but does not significantly affect dynamics.
A, Shear rate along the width of a 60 µm tall by 250 µm wide channel at 8 µL/min flow rate.
Analysis zone corresponds to 75% area of the entire clot. B, Shear rate along the width of a 120
µm tall by 250 µm wide channel at 8 µL/min flow rate. Analysis zone corresponds to 75% area of
the entire clot.

Supplemental Figure II: Procedure to fix clots to image with confocal before and after
shear
To look at clots before and after shear, device 1 is fixed before and device 2 is fixed after. The
fixing procedure is comprised of 3 minutes of BSA perfusion followed by 3 minutes of
Paraformaldehyde perfusion. In this device 1, these steps occur right after 3 minutes of clot
growth. In device 2, this occurs after the 17-minute shear period.
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Supplemental Figure III: A 60 µm tall channel can be used to look at clot stability under
certain conditions
High CTI WB was perfused at 100 s-1 over collagen followed by HBS at 1000 s-1 (Δ). (A)
Normalized platelet FI with HBS perfused at initial shear rate of 100 s-1 (blue) or 1000 s-1 (red).
Data are expressed as mean ± SD with n=8 clots for 1 donor. (B) Representative clot images at 3
minutes and 20 minutes with platelets in red. Scale bar is 100 µm.

Supplemental Figure IV: Blood can be swapped out for buffer at later time points
High CTI WB was perfused at 100 s-1 over collagen/TF for either 180, 270, or 360 sec by HBS at
1000 s-1 (Δ). The extended height of the channel allows for longer windows to look at stability.
Data are expressed as mean ± SD for n=8 clots for 1 donor.
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Supplemental Figure V: Procedure to calculate percent contraction
Images were first binarized at half the average fluorescence intensity. The middle 100 pixels of
the clot are measured in the direction of flow. A height is determined for each pixel by finding the
topmost and bottommost white pixel in each x-direction. The lengths at 7.5 and 15 minutes can
then be subtracted to get a percent contraction.
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